Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

Kavita M Dhodapkar Adam David Cohen Akhilesh Kaushal Alfred L Garfall Renee Julia Manalo Allison R CarrSamuel S McCachrenEdward A Stadtmauer Simon F Lacey Jan Joseph Melenhorst Carl H June Michael C Milone Madhav V Dhodapkar

Published in: Blood cancer discovery (2022)

There is an unmet need to identify determinants of durable responses following BCMA CAR T therapy of myeloma. High-dimensional analysis of the TME was performed to identify features of immune and tumor cells that correlate with survival and suggest several strategies to improve outcomes following CAR T therapy. See related commentary by Graham and Maus, p. 478. This article is highlighted in the In This Issue feature, p. 476.

Keyphrases

bone marrow
machine learning
mesenchymal stem cells
stem cells
drug induced